Prussian Blue Nanozyme with Multienzyme Activity Reduces Colitis in Mice.

The overproduction of reactive oxygen species (ROS) is central to the progression of inflammatory bowel disease (IBD), which may be the potential therapeutic target. Prussian blue (PB) nanoparticles with good biosafety can act as an artificial nanozyme, effectively scavenging ROS. To date, PB-based nanomaterials have not been developed and utilized for treatment of IBD. In this study, poly(vinylpyrrolidone)-modified Prussian blue (PPB) nanoparticles are constructed with good physiological stability and biosafety by a simple and efficient method. The prepared PPBs with capabilities of scavenging ROS and inhibiting proinflammatory cytokine significantly reduce colitis in mice without distinct side effects via intravenous administration. This report provides a demonstration of the protective effect of PB-based nanomedicine against IBD in living animals, offering hope and a potential alternative treatment option for patients suffering from IBD.

[1]  R. Langer,et al.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease. , 2017, Nano today.

[2]  Hong Cheng,et al.  Cancer Cell Membrane Camouflaged Cascade Bioreactor for Cancer Targeted Starvation and Photodynamic Therapy. , 2017, ACS nano.

[3]  D. Merlin,et al.  Nanotherapeutics for the treatment of inflammatory bowel disease , 2017, Expert review of gastroenterology & hepatology.

[4]  Yuanyi Zheng,et al.  Enabling Prussian Blue with Tunable Localized Surface Plasmon Resonances: Simultaneously Enhanced Dual-Mode Imaging and Tumor Photothermal Therapy. , 2016, ACS nano.

[5]  Ruibing Wang,et al.  A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. , 2016, Biomaterials.

[6]  Jinho Park,et al.  Bilirubin Nanoparticles as a Nanomedicine for Anti-inflammation Therapy. , 2016, Angewandte Chemie.

[7]  Yu Zhang,et al.  Prussian Blue Nanoparticles as Multienzyme Mimetics and Reactive Oxygen Species Scavengers. , 2016, Journal of the American Chemical Society.

[8]  C. Patra.  Prussian blue nanoparticles and their analogues for application to cancer theranostics. , 2016, Nanomedicine.

[9]  John Youshia,et al.  Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases , 2016, Expert opinion on drug delivery.

[10]  Yuanyi Zheng,et al.  A Prussian Blue‐Based Core–Shell Hollow‐Structured Mesoporous Nanoparticle as a Smart Theranostic Agent with Ultrahigh pH‐Responsive Longitudinal Relaxivity , 2015, Advanced materials.

[11]  L. Ferder,et al.  Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. , 2015, World journal of biological chemistry.

[12]  Haitao Guo,et al.  Inflammasomes: mechanism of action, role in disease, and therapeutics , 2015, Nature Medicine.

[13]  Yuanyi Zheng,et al.  A Versatile Nanotheranostic Agent for Efficient Dual‐Mode Imaging Guided Synergistic Chemo‐Thermal Tumor Therapy , 2015 .

[14]  Zhuang Liu,et al.  PEGylated Prussian blue nanocubes as a theranostic agent for simultaneous cancer imaging and photothermal therapy. , 2014, Biomaterials.

[15]  Y. Janssen-Heininger,et al.  Hydrogen Peroxide as a Damage Signal in Tissue Injury and Inflammation: Murderer, Mediator, or Messenger? , 2014, Journal of cellular biochemistry.

[16]  S. Reddy,et al.  Reactive oxygen species in inflammation and tissue injury. , 2014, Antioxidants & redox signaling.

[17]  S. Grivennikov.  Inflammation and colorectal cancer: colitis-associated neoplasia , 2013, Seminars in Immunopathology.

[18]  C. Glass,et al.  Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities , 2013, Science.

[19]  Xiuli Yue,et al.  Prussian blue nanoparticles operate as a new generation of photothermal ablation agents for cancer therapy. , 2012, Chemical communications.

[20]  Yu Zhang,et al.  A Hydrogen Peroxide‐Responsive O2 Nanogenerator for Ultrasound and Magnetic‐Resonance Dual Modality Imaging , 2012, Advanced materials.

[21]  Toru Yoshitomi,et al.  An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. , 2012, Gastroenterology.

[22]  M. Vatn,et al.  Health‐Related Quality of Life in Patients with Ulcerative Colitis After a 10‐year Disease Course: Results from the IBSEN Study , 2012, Inflammatory bowel diseases.

[23]  Hong Zhu,et al.  Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence , 2012, Experimental biology and medicine.

[24]  Fiona Powrie,et al.  Intestinal homeostasis and its breakdown in inflammatory bowel disease , 2011, Nature.

[25]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.